Full-Time

Private Equity Product Specialist

Posted on 10/30/2024

Viking Global

Viking Global

51-200 employees

Fintech
Financial Services

Compensation Overview

$150k - $200kAnnually

+ Discretionary Bonus

Senior

New York, NY, USA

Category
Private Equity
Finance & Banking
Requirements
  • Excellent communication and interpersonal skills with the ability to articulate thoughts well, both verbally and in writing
  • Prior investor relations or product specialist experience in private equity (preferred). Exposure across multiple products and fund structures is a plus
  • Strong judgment and problem-solving capabilities
  • Teamwork orientation
  • Outstanding attention to detail, organizational skills, focus on process, ability to prioritize multiple projects, and willingness to take ownership of and be accountable for a variety of tasks
  • A strong knowledge of finance and investing
  • An undergraduate degree with a strong academic record
  • Five or more years of experience in a client-oriented investor relations role, investment banking, or consulting
Responsibilities
  • Identifying salient messages for investor communications about investments, the business, the market environment, and competitive positioning. Crafting written and verbal communications on behalf of the firm, including investor letters, presentation materials, speeches, operational due diligence materials, emails, and talking points
  • Serving as liaison between the investor relations client facing team and investment staff
  • Monitoring the competitive landscape and industry dynamics, including through the use of databases
  • Leading cross-functional fund launch and improvement projects
  • Preparing regular updates for the broader firm on investor relations initiatives

Company Stage

N/A

Total Funding

$16.7B

Headquarters

Greenwich, Connecticut

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Viking Global benefits from FDA's Breakthrough Device Designation for Magenta Medical's Elevate System.
  • Their investment in Diagonal Therapeutics supports novel approaches in agonist antibody development.
  • Viking Global's involvement in Antheia's funding positions them for biopharmaceutical manufacturing advancements.

What critics are saying

  • Competition in the heart pump market may impact returns from Magenta Medical investment.
  • Challenges in program selection could delay new biotech company launches with AbCellera.
  • Diagonal Therapeutics' platform may fail to achieve clinical proof-of-concept, risking investment.

What makes Viking Global unique

  • Viking Global Investors is actively investing in innovative biotech and medical technologies.
  • Their collaboration with AbCellera and ArrowMark focuses on pioneering antibody drug programs.
  • Viking Global's diverse portfolio includes investments in heart pumps, biopharmaceuticals, and digital payments.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE